Lantern Pharma gets Nasdaq notice: MVLS under $35M for 30 days, 180 days to regain compliance

Lantern Pharma Inc.

Nasdaq notice dated September 25, 2026: market value of listed securities (MVLS) fell below the $35,000,000 minimum for 30 consecutive business days.
Company also does not meet Nasdaq Listing Rules 5550(b)(1) and 5550(b)(3), per the notice.
Has until March 24, 2027 (180 calendar days) to regain compliance under Listing Rule 5810(c)(3)(C).
To cure via MVLS, LTRN stock must close at $35,000,000 or more for a minimum of 10 consecutive business days.
If compliance is not regained, the company expects Nasdaq to notify it that its securities are subject to delisting from the Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.